Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: Patient level meta-analysis

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Valgimigli, Marco ^a   Sabaté, Manel ^b   Kaiser, Christoph ^c   Brugaletta, Salvatore ^b   De La Torre Hernandez, Jose Maria ^d   Galatius, Soeren ^e   Cequier, Angel ^f   Eberli, Franz ^g   De Belder, Adam ^h   Serruys, Patrick W ^a   Ferrante, Giuseppe ⁱ  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g TRIEMLI HOSPITAL   (Switzerland)

^h UK   (United Kingdom)

ⁱ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE CORONARY SYNDROME; ARTICLE; BARE METAL STENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; COBALT CHROMIUM EVEROLIMUS ELUTING STENT; DEVICE SAFETY; DRUG ELUTING STENT; HEART INFARCTION; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; RISK BENEFIT ANALYSIS; STENT THROMBOSIS; TARGET VESSEL REVASCULARIZATION; TREATMENT DURATION; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; COMPLICATION; CORONARY ARTERY DISEASE; MORTALITY; MYOCARDIAL INFARCTION; STENT; THROMBOSIS; TREATMENT OUTCOME;

CHROMIUM; COBALT; EVEROLIMUS; RAPAMYCIN;

CHROMIUM; COBALT; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; HUMANS; MYOCARDIAL INFARCTION; SIROLIMUS; STENTS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84910086529     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g6427     Document Type: Article

References (39)

1. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Eng J Med 2004;350:221-31.
2. Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 2008;299:1788-99.
3. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-9.
4. Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007;357:1393-402.
5. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-68.
6. Kalesan B, Pilgrim T, Heinimann K, Raber L, Stefanini GG, Valgimigli M, et al. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012;33:977-87.
7. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010;375:201-9.
8. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008;299:1903-13.
9. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362:1663-74.
10. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010;363:136-46.
11. Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, et al. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 2010;363:2310-9.
12. Sabate M, Cequier A, Iniguez A, Serra A, Hernandez-Antolin R, Mainar V, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012;380:1482-90.
13. Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, et al. Two-year outcomes after first-or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study (PRODIGY). JACC Cardiovasc Interv 2014;7:20-8.
14. Higgins JP, Altman DG, Sterne JAC, eds. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews, version 5.1.0 (updated March 2011). Cochrane Collaboration, 2011. www.cochranehandbook.org.
15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
16. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
17. De Belder A, de la Torre Hernandez JM, Lopez-Palop R, O'Kane P, Hernandez F, Strange J, et al. A prospective randomized trial of everolimus-eluting stents versus bare metal stents in octogenarians: Xience or Vision stents for the management of angina in the elderly-the Xima Trial. J Am Coll Cardiol 2013;63:1371-5.
18. Sabate M, Brugaletta S, Cequier A, Iniguez A, Serra A, Hernadez-Antolin R, et al. The EXAMINATION Trial (everolimus-eluting stents versus bare-metal stents in st-segment elevation myocardial infarction): 2-year results from a multicenter randomized controlled trial. JACC Cardiovasc Interv 2014;7:64-71.
19. Valgimigli M, Campo G, Percoco G, Monti M, Ferrari F, Tumscitz C, et al. Randomized comparison of 6-versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention design and rationale for the prolonging dual-antiplatelet treatment after grading stent-induced intimal hyperplasia study (PRODIGY). Am Heart J 2010;160:804-11.
20. Beijk MA, Neumann FJ, Wiemer M, Grube E, Haase J, Thuesen L, et al. Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery stenosis (the SPIRIT FIRST Trial). EuroIntervention 2007;3:206-12.
21. Therneau TM, Grambsch PM, Pankratz VS. Penalized survival models and frailty. J Comput Graph Stat 2003;12:156-75.
22. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
24. Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof 2002;25:76-97.
25. De la Torre-Hernandez JM, Alfonso F, Hernandez F, Elizaga J, Sanmartin M, Pinar E, et al. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 2008;51:986-90.
26. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med 2006;354:483-95.
27. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007;115:1440-55.
28. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-8.
29. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008;51:172-209.
30. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med 2013;368:254-65.
31. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393-402.
32. Valgimigli M, Borghesi M, Tebaldi M, Vranckx P, Parrinello G, Ferrari R. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study (PRODIGY). Eur Heart J 2013;34:909-19.
33. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of Xience/Promus versus Cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study. Circulation 2011;125:505-13.
34. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011;123:1400-9.
35. Rogers C, Edelman ER. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation 1995;91:2995-3001.
36. Xie X, Guidoin R, Nutley M, Zhang Z. Fluoropassivation and gelatin sealing of polyester arterial prostheses to skip preclotting and constrain the chronic inflammatory response. J Biomed Mater Res B Appl Biomater 2010;93:497-509.
37. Brener SJ, Kereiakes DJ, Simonton CA, Rizvi A, Newman W, Mastali K, et al. Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the clinical evaluation of the XIENCE V Everolimus eluting coronary stent system in the treatment of subjects with de novo native coronary artery lesions trial. Am Heart J 2013;166:1035-42.
38. Raber L, Juni P, Nuesch E, Kalesan B, Wenaweser P, Moschovitis A, et al. Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization. J Am Coll Cardiol 2011;57:2143-51.
39. Gada H, Kirtane AJ, Newman W, Sanz M, Hermiller JB, Mahaffey KW, et al. 5-Year Results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). JACC Cardiovasc Interv 2013;6:1263-6.